Anthony E Sisk Jr
Overview
Explore the profile of Anthony E Sisk Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
158
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Molgora B, Mukherjee S, Baumel-Alterzon S, Santiago F, Muratore K, Sisk Jr A, et al.
PLoS Negl Trop Dis
. 2023 Oct;
17(10):e0011693.
PMID: 37871037
Trichomonas vaginalis is a human infective parasite responsible for trichomoniasis-the most common, non-viral, sexually transmitted infection worldwide. T. vaginalis resides exclusively in the urogenital tract of both men and women....
2.
Fackelmayer O, Rodriguez E, Sisk Jr A, Livhits M
Diagn Pathol
. 2023 Oct;
18(1):112.
PMID: 37833805
Schwannomas are benign, generally indolent tumors of neural crest origin and comprise the most common histologic tumor of peripheral nerves. Schwannomas are a rare histology for retroperitoneal tumors and very...
3.
Unterrainer L, Sisk Jr A, Czernin J, Shuch B, Calais J, Hotta M
J Nucl Med
. 2023 Jun;
64(10):1660-1661.
PMID: 37321822
No abstract available.
4.
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena
Khoo A, Liu L, Sadun T, Salmasi A, Pooli A, Felker E, et al.
J Hematol Oncol
. 2022 May;
15(1):48.
PMID: 35505417
Multiparametric magnetic resonance imaging (mpMRI) is an emerging standard for diagnosing and prognosing prostate cancer, but ~ 20% of clinically significant tumors are invisible to mpMRI, as defined by the...
5.
Mendhiratta N, Muraki P, Sisk Jr A, Shuch B
Urol Oncol
. 2021 May;
39(6):327-337.
PMID: 34034966
Kidney cancer is the 13th most common malignancy globally, and the incidence is rising. Papillary renal cell carcinoma is the second most common subtype, comprising 10-15% of renal cell carcinomas....
6.
Pooli A, Johnson D, Shirk J, Markovic D, Sadun T, Sisk Jr A, et al.
J Urol
. 2020 Oct;
205(2):444-451.
PMID: 33026934
Purpose: Oncologic efficacy of focal therapies in prostate cancer depends heavily on accurate tumor size estimation. We aim to evaluate the agreement between radiologic tumor size and pathological tumor size,...
7.
Salami S, Tosoian J, Nallandhighal S, Jones Jr T, Brockman S, Elkhoury F, et al.
Eur Urol
. 2020 Jul;
79(4):456-465.
PMID: 32631746
Background: The potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear. Objective: To interrogate the molecular and biological features of low-grade PCa...
8.
Simopoulos D, Sisk Jr A, Priester A, Felker E, Kwan L, Delfin M, et al.
BJU Int
. 2019 Jan;
124(2):275-281.
PMID: 30694605
Objective: To study the relationship of maximum cancer core length (MCCL), on targeted biopsy (TB) of magnetic resonance imaging (MRI)-visible index lesions, to volume of that tumour found at radical...
9.
Houlahan K, Salmasi A, Sadun T, Pooli A, Felker E, Livingstone J, et al.
Eur Urol
. 2019 Jan;
76(1):18-23.
PMID: 30685078
Multiparametric magnetic resonance imaging (mpMRI) has transformed the management of localized prostate cancer by improving identification of clinically significant disease at diagnosis. Approximately 20% of primary prostate tumors are invisible...
10.
Salmasi A, Faiena I, Wu J, Sisk Jr A, Sachveda A, Vandel J, et al.
Urol Oncol
. 2018 Aug;
36(9):401.e19-401.e25.
PMID: 30064933
Background: In the era of increasing scrutiny of delivery of quality care, efforts to decrease surgical overtreatment of insignificant prostate cancer (iCaP) continue. Objective: To quantify the incidence of surgical...